Patient Preferences for Attributes of Chemotherapy for Lung Cancer: Discrete Choice Experiment Study in Japan

被引:1
|
作者
Sugitani, Yasuo [1 ,2 ]
Ito, Kyoko [3 ]
Ono, Shunsuke [2 ]
机构
[1] Chugai Pharmaceut Co Ltd, Biometr Dept, Tokyo, Japan
[2] Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmaceut Regulat & Sci, Tokyo, Japan
[3] Chugai Pharmaceut Co Ltd, Sustainabil Dept, Tokyo, Japan
关键词
patient centricity; Japanese patient preferences; lung cancer; discrete choice experiment; conjoint analysis; hierarchical bayes model; DECISION-MAKING; AMERICAN SOCIETY; OUTCOMES; SURVEILLANCE; BENEFITS; THERAPY;
D O I
10.3389/fphar.2021.697711
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Our study objective was to determine lung cancer chemotherapy attributes that are important to patients in Japan. A discrete choice experiment survey in an anonymous web-based questionnaire format with a reward was completed by 200 lung cancer patients in Japan from November 25, 2019, to November 27, 2019. The relative importance of patient preferences for each attribute was estimated using a conditional logit model. A hierarchical Bayesian logit model was also used to estimate the impact of each demographic characteristic on the relative importance of each attribute. Of the 200 respondents, 191 with consistent responses were included in the analysis. In their preference, overall survival was the most important, followed by diarrhea, nausea, rash, bone marrow suppression (BMS), progression-free survival, fatigue, interstitial lung disease, frequency of administration, and duration of administration. The preferences were influenced by demographic characteristics (e.g., gender and age) and disease background (e.g., cancer type and stage). Interestingly, the experience of cancer drug therapies and adverse events had a substantial impact on the hypothetical drug preferences. For the Japanese lung cancer patients, improved survival was the most important attribute that influenced their preference for chemotherapy, followed by adverse events, including diarrhea, nausea, rash, and BMS. The preferences varied depending on the patient's demographic and experience. As drug attributes can affect patient preferences, pharmaceutical companies should be aware of the patient preferences and develop drugs that respond to segmented market needs.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Quantitative Patient Preferences for Lung cancer treatment: A discrete choice experiment in Japan
    Sugitani, Yasuo
    Ito, Kyoko
    Ono, Shunsuke
    [J]. CANCER SCIENCE, 2021, 112 : 590 - 590
  • [2] DEVELOPING ATTRIBUTES AND ATTRIBUTE-LEVELS FOR A DISCRETE CHOICE EXPERIMENT ON LUNG CANCER PATIENT'S PREFERENCES FOR DRUG THERAPIES
    Monteiro, A.
    Santos, M.
    Fontes, L. S.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A116 - A116
  • [3] Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China
    Sun, Hui
    Wang, Huishan
    Xu, Ningze
    Li, Junling
    Shi, Jufang
    Zhou, Naitong
    Ni, Ming
    Hu, Xianzhi
    Chen, Yingyao
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 1701 - 1709
  • [4] Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study
    Yang, Min
    Chao, Jingdong
    Fillbrunn, Mirko
    Mallya, Usha G.
    Wang, Min -Jung
    Franke, Leigh
    Cohn, Lauren
    Kamat, Siddhesh
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2022, 16 : 2649 - 2661
  • [5] Line of Therapy and Patient Preferences Treating Lung Cancer: A Discrete-Choice Experiment
    Bridges, J.
    Roy, U. Basu
    Janssen, E.
    Ferris, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S378 - S379
  • [6] Patient preferences for important attributes of bipolar depression treatments: a discrete choice experiment
    Ng-Mak, Daisy
    Poon, Jiat-Ling
    Roberts, Laurie
    Kleinman, Leah
    Revicki, Dennis A.
    Rajagopalan, Krithika
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 35 - 44
  • [7] Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment
    Liu, Frank Xiaoqing
    Witt, Edward A.
    Ebbinghaus, Scot
    Beyer, Grace DiBonaventura
    Shinde, Reshma
    Basurto, Enrique
    Joseph, Richard W.
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 1389 - 1399
  • [8] Patient Preferences for Provider Choice: A Discrete Choice Experiment
    van den Broek-Altenburg, Eline M.
    Atherly, Adam J.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2020, 26 (07): : E219 - +
  • [9] Patient Preferences for Provider Choice: A Discrete Choice Experiment
    van den Broek-Altenburg, Eline
    Atherly, Adam
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2020, 13 (01): : 142 - 142
  • [10] Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment
    Janse, Sarah
    Janssen, Ellen
    Huwig, Tanya
    Basu Roy, Upal
    Ferris, Andrea
    Presley, Carolyn J.
    Bridges, John F. P.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 643 - 653